( thany pharmaceutical product there ar...)Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder,Health

th any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

    (1) Gliatto, Michael, F.  "Generalized Anxiety Disorder."  American Family

        Physicians, Vol. 62/No. 7, October 1, 2000.

    (2) Leon, Andrew et al. "Assessing Psychiatric Impairment in Primary Care

        with the Sheehan Disability Scale." Int'l J. Psychiatry in Medicine.

        Vol. 27 (2), 1997, pp. 93-105

    (3) Cymbalta Prescribing Information, www.cymbalta.com

    (4) Mental Health America.  "Generalized Anxiety Disorder." Available at:

        http://www1.nmha.org/camh/anxiety/gad.cfm. Accessed on January 17,

        2007.

    (5) National Institute of Mental Health (NIMH).  "Anxiety Disorders."

        Available at: http://www.nimh.nih.gov/publicat/anxiety.cfm#anx7.

        December 2006.

    (6) APA. "Diagnostic and Statistical Manual of Mental Disorders - Fourth

        Edition." 1994, pp 472-476.

    (7) APA. "Diagnostic and Statistical Manual of Mental Disorders - Fourth

        Edition." 1994, pp 472-476.


    

CONTACT: Tamara Hull (US), +1-317-651-9116, mobile: +1-317-614-5132, orDavid Shaffer (OUS), +1-317-651-3710, mobile: +1-317-614-5106, both of EliLilly and Company

Ticker Symbol: (:LLY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

'"/>




Page: 1 2 3 4 5 6
Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
3. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
4. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
9. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
10. Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
11. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon